Komori
JCR Pharmaceuticals (4552) · RiskMaterialised

Termination of the JR-141 Partnership Agreement with Takeda Pharmaceutical Company

First written in FY2024. 1 of 1 entries say "Materialised", first in FY2024. Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Termination of the JR-141 regional partnership agreement with TakedaA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024MaterialisedAnnual report

    「The exclusive co-development and licensing agreement with Takeda Pharmaceutical Company Limited for the next-generation recombinant fusion protein JR-141 (INN: pabinafusp alfa) in specified territories ended in June 2024.」

    Regarding the risk of changes to existing overseas co-development and licensing agreements, the company disclosed that its agreement with Takeda Pharmaceutical Company Limited covering specified territories for JR-141 ended in June 2024. The company stated that its group would continue the clinical development program.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.